Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 2/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.41 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.41 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.41 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.33 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.31 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.31 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18505882 | 1.00 | SLC6A1 (0.41) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL23063091 | 1.00 | SLC6A1 (0.41) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL10507058 | 0.88 | HRH3 (0.37) | SLC6A1SLC6A11KCNH2HRH4HRH3 | |
| SCHEMBL247608 | 0.86 | GNAO1 (0.36) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| Hydrochloric Acid SCHEMBL6150116 | 0.84 | GNAO1 (0.39) | KCNH2GNAI3GNAO1GNAI1 | |
| SCHEMBL5649067 | 0.82 | GNAO1 (0.36) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL22989589 | 0.81 | CYP1A2 (0.30) | KCNH2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10562710 | 0.81 | SLC6A1 (0.39) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL30150910 | 0.81 | SLC6A1 (0.39) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL25960704 | 0.81 | SLC6A1 (0.39) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112533913-A | Novel compounds | 英夫拉索姆有限公司 | 2021-03-19 | — | — | CN | disclosed |
| EP-3788041-A1 | NOVEL COMPOUNDS | Inflazome Limited (IE) | 2021-03-10 | — | — | EP | disclosed |
| CN-108026085-A | Fumidil alcohol heterocyclic compound and preparation and use its method | 扎夫根股份有限公司 | 2018-05-11 | — | — | CN | disclosed |
| EP-2678349-B1 | C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE | TAISHO PHARMACEUTICAL CO LTD (JP) | 2016-01-13 | — | — | EP | disclosed |
| US-9139609-B2 | C-4″ position substituted macrolide derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-09-22 | — | — | US | disclosed |
| US-20140046043-A1 | C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2014-02-13 | — | — | US | disclosed |
| EP-2678349-A1 | C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2014-01-01 | — | — | EP | disclosed |
| WO-2012115256-A1 | C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-30 | — | — | WO | disclosed |
| US-5281612-A | Naphthyridine antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1994-01-25 | — | — | US | disclosed |
| EP-0254955-B1 | Substituted pyrido[2,3-b][1,4]benzodiazepin-6-ones, process for their preparation and medicaments containing these compounds | Dr. Karl Thomae GmbH (DE) | 1992-05-27 | — | — | EP | disclosed |
| US-4971966-A | BRADYCARDIAL, CARDIOVASCULAR DISORDERS | KARL THOMAE GMBH (DE) | 1990-11-20 | — | — | US | disclosed |
| US-4777175-A | (NAPHTHYRIDINE, QUINOLINE) CARBOXYLIC ACID | WARNER-LAMBERT COMPANY (US) | 1988-10-11 | — | — | US | disclosed |
| US-4771054-A | QUINOLINE CARBOXYLIC ACID | WARNER-LAMBERT COMPANY (US) | 1988-09-13 | — | — | US | disclosed |
| EP-0254955-A2 | Substituted pyrido[2,3-b][1,4]benzodiazepin-6-ones, process for their preparation and medicaments containing these compounds | Dr. Karl Thomae GmbH (DE) | 1988-02-03 | — | — | EP | disclosed |
| US-4665079-A | QUINOLINE DERIVATIVES | WARNER-LAMBERT COMPANY (US) | 1987-05-12 | — | — | US | disclosed |
| US-4638067-A | NAPHTHYRIDINE AND QUINOLINE CARBOXYLIC ACIDS | WARNER-LAMBERT CO. (US) | 1987-01-20 | — | — | US | disclosed |
| EP-0153163-A2 | 7-Substituted-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids; 7-substituted-1-cyclopropyl-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acids; their derivatives; and a process for preparing the compounds | WARNER-LAMBERT COMPANY (US) | 1985-08-28 | — | — | EP | disclosed |
| US-4041032-A | ANTIEMATICS, GASTRIC MOTILITY STIMULANTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JA) | 1977-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140046043-A1 | C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE | MRPL21, MRPS34, MRPL37 | SLC6A1 4764/4885GABRA5 4556/4885GABRB2 4004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.